<DOC>
	<DOCNO>NCT02587689</DOCNO>
	<brief_summary>The purpose study determine whether autologous T cell bear chimeric antigen receptor specifically recognize ( Mucin 1 ) MUC1 safe effective patient relapse refractory solid tumor .</brief_summary>
	<brief_title>Phase I/II Study Anti-Mucin1 ( MUC1 ) CAR T Cells Patients With MUC1+ Advanced Refractory Solid Tumor</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>Male female subject MUC1+ malignancy patient available curative treatment option limit prognosis ( several month &lt; 2 year survival ) currently available therapy enrol : Eligible disease : MUC1+ hepatocellular carcinoma , nonsmall cell lung cancer , pancreatic carcinoma triplenegative basallike breast carcinoma . 1 . Hepatocellular carcinoma ( HCC ) Clinical diagnosis HCC confirm histopathological examination surgical sample patient ; 2 . Nonsmall cell lung cancer Refractory recurrent histologically cytologically confirm ; unresectable ; nonsquamous NSCLC must test epidermal growth factor receptor ( EGFR ) mutation anaplastic lymphoma kinase ( ALK ) translocation positive receive appropriate tyrosine kinase inhibitor therapy prior enrollment ; 3 . Pancreatic carcinoma Patients histologic verification carcinoma pancreas ( T13 , N01 ) undergone surgical resection within past 4 12 week . Patients R1 resection exclude ; 4 . Triplenegative basallike breast carcinoma Patients basallike breast carcinoma must confirm triple negative ( estrogen receptor negative [ ER ] / progesterone receptor ( PR ) negative [ PR ] / human epidermal growth factor receptor2 ( HER2 ) negative [ HER2 ] ) . MUC1 express malignancy tissue immunohistochemical ( IHC ) . Eastern cooperative oncology group ( ECOG ) performance status 01 karnofsky performance status ( KPS ) score high 60 . Patients 18 year age old , must life expectancy &gt; 12 week . Adequate venous access apheresis venous sampling , contraindication leukapheresis . Females childbearing potential must negative pregnancy test subject must agree use effective method contraception two week last infusion CAR T cell . Adequate bone marrow , liver renal function assess follow laboratory requirement : White blood cell count ( WBC ) ≥ 2500c/ml , Platelets ≥ 50×10^9/L , Hb ≥ 9.0g/dL , lymphocyte ( LY ) ≥ 0.7×10^9/L , LY % ≥ 15 % , Alb ≥ 2.8g/dL , serum lipase amylase &lt; 1.5×upper limit normal , serum creatinine ≤ 2.5mg/dL , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 5×upper limit normal , serum total bilirubin ≤ 2.0mg/dL . These test must conduct within 7 day prior registration . Ability give inform consent . The transduction efficiency T cell less 10 % amplification T cell via artificial antigen present cell ( aAPC ) stimulation le 5 time . Patients symptomatic central nervous system ( CNS ) involvement . Pregnant nursing woman may participate . Known HIV , hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) infection . Serious illness medical condition would permit patient manage accord protocol , include active uncontrolled infection , major cardiovascular , coagulation disorder , respiratory immune system , myocardial infarction , cardiac arrhythmia , obstructive/restrictive pulmonary disease , psychiatric emotional disorder . History severe immediate hypersensitivity agent include cyclophosphamide , fludarabine , aldesleukin . Concurrent use systemic steroid . Recent current use inhale steroid exclusionary . Previously treatment gene therapy product . The existence unstable active ulcer gastrointestinal bleeding . Patients portal vein vascular invasion extrahepatic , exclude study . Patients history organ transplantation wait organ transplantation . Patients need anticoagulant therapy ( warfarin heparin ) . Patients need longterm antiplatelet therapy ( aspirin dose &gt; 300mg/d ; clopidogrel dose &gt; 75mg/d ) . Patients treat radiotherapy within 4 week prior first apheresis . Patients use fludarabine cladribine chemotherapy within two year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>